Document is current
Any future updates will be listed below
-
Authors
Mateo, Sandra V.
Vidal-Correoso, Daniel
Muñoz-Morales, Ana M.
Jover-Aguilar, Marta
Alconchel, Felipe
de la Peña, Jesús
Martínez-Alarcón, Laura
López-López, Víctor
Ríos-Zambudio, Antonio
Cascales, Pedro
Pons, José A.
Ramírez, Pablo
Pelegrín, Pablo https://orcid.org/0000-0002-9688-1804
Baroja-Mazo, Alberto https://orcid.org/0000-0001-5212-5006
-
Funding
Funding for this research was provided by:
Fundación Mutua Madrileña (AP171362019)
Fundación Séneca (22257PDC23)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI20/00185, DTS23/00013, FI21/00073, PI23/00321)
- License Information
-
More Information
Article History
Received: 18 April 2024
Revised: 17 May 2024
Accepted: 22 May 2024
First Online: 30 May 2024
Competing interests
: The authors declare no competing interests. A.B.-M., P.P. and L.M-A are co-founders of Viva in vitro diagnostics S.L, a company focused on utilizing the NLRP3 inflammasome as a disease biomarker. A.B-M. is also co-inventor listed on a provisional patent application for an in vitro method predicting organ transplant rejection. However, it is important to note that this research was conducted independently, without any commercial or financial associations that might be considered a conflict of interest. None of the other authors involved in this manuscript have any conflicts of interest to disclose.
: All liver transplant patients who received one of the studied donated livers participated in the present study under informed consent. The present study was approved by the ethical committee of Hospital Clínico Universitario Virgen de la Arrixaca (2019-6-2-HCUVA) and conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
